SCHEMBL20944007

SCHEMBL20944007

CCOC(=O)c1cc(C#N)cc(OC)c1OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FNTA P49354 1/20 0.45
FNTB P49356 1/20 0.45
HSD17B10 Q99714 3/20 0.45
TSHR P16473 1/20 0.45
KDM4E B2RXH2 6/20 0.44
ATM Q13315 2/20 0.44
GLA P06280 1/20 0.44
ALDH1A1 P00352 5/20 0.44
DPP4 P27487 2/20 0.44
HPGD P15428 2/20 0.44
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
MAPT P10636 3/20 0.43
GAA P10253 2/20 0.43
TP53 P04637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27758051 0.82 KDM4E (0.42) HSD17B10TSHRKDM4EALDH1A1HPGD
SCHEMBL7986113 0.81 PDE5A (0.48) FNTAFNTBHSD17B10TSHRKDM4E
SCHEMBL20943940 0.78 ALDH1A1 (0.51) HSD17B10TSHRKDM4EALDH1A1DPP4
SCHEMBL6883767 0.74 TSHR (0.55) HSD17B10TSHRKDM4EATMGLA
SCHEMBL509507 0.74 ACHE (0.52) KDM4EALDH1A1HPGDCYP1A2CYP3A4
SCHEMBL12326381 0.74 KDM4E (0.51) HSD17B10TSHRKDM4EATMGLA
SCHEMBL3681739 0.72 KDM4E (0.50) HSD17B10TSHRKDM4EATMGLA
SCHEMBL2900687 0.72 KMT2A (0.65) TSHRKDM4EALDH1A1DPP4KMT2A
SCHEMBL7390366 0.72 MAPT (0.45) FNTAFNTBKDM4EGLAALDH1A1
SCHEMBL7671086 0.72 MAOB (0.53) FNTAFNTBHSD17B10TSHRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111295382-B Bridged bicyclic compounds as farnesyl ester X receptor modulators 百时美施贵宝公司 2024-02-02 CN disclosed
EP-3704113-B1 BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS BRISTOL MYERS SQUIBB CO (US) 2023-10-11 EP disclosed
EP-3704113-B1 BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS BRISTOL MYERS SQUIBB CO (US) 2023-10-11 EP disclosed
EP-3704113-A1 BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS Bristol-Myers Squibb Company (US) 2020-09-09 EP disclosed
US-10730863-B2 Bridged bicyclic compounds as farnesoid X receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2020-08-04 US disclosed
US-10730863-B2 Bridged bicyclic compounds as farnesoid X receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2020-08-04 US disclosed
US-20190127358-A1 BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2019-05-02 US disclosed
US-20190127358-A1 BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2019-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190127358-A1 BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS NR1H4, FXR1, NR1H2 FNTA 18/4885FNTB 20/4885HSD17B10 425/4885
US-10730863-B2 Bridged bicyclic compounds as farnesoid X receptor modulators NR1H4, FXR1, NR1H2 FNTA 18/4885FNTB 20/4885HSD17B10 425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.